Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-259-7 | CAS number: 93-58-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study without detailed documentation
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 985
- Report date:
- 1985
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Methyl benzoate
- EC Number:
- 202-259-7
- EC Name:
- Methyl benzoate
- Cas Number:
- 93-58-3
- Molecular formula:
- C8H8O2
- IUPAC Name:
- methyl benzoate
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Interfauna UK Limited, Wyton, Huntingdon
- Age at study initiation: 5 - 8 weeks
- Weight at study initiation: males: 132 -197 g, females 134 -175 g
- Fasting period before study: overnight fast immediately before dosing and for 2 hours after dosing
- Housing: in groups of up to 5 by sex in polypropylene cages with sawdust bedding
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): mains drinking water ad libitum
- Acclimation period: >= 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-23
- Humidity (%): 40 -68
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: 1985-10-25
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- MAXIMUM DOSE VOLUME APPLIED: 3.7 mL/kg
- Doses:
- 2000 mg/kg
As treatment-related mortalities occurred, the following doses were tested in addition:
500 mg/kg
1000 mg/kg
4000 mg/kg - No. of animals per sex per dose:
- 5 males, 5 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: observations 1 and 4 hours after dosing and subsequently once daily for 14 days, weighing on day of treatment and day 7 and 14
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, necropsy - Statistics:
- Method of Weil C.S. (1952) Biometrics 8,249 to calculate LD50 an 95 % confidence limits
Results and discussion
Effect levelsopen allclose all
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 2 000 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 1 587 - 2 520
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 1 625 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 1 231 - 2 144
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 - < 4 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- 500 mg/kg: 0/10
1000 mg/kg: 0/10
2000 mg/kg: 5/10 (1 male died on day 0, 3 males on day 1, 1 female on day 1)
4000 mg/kg: 10/10 (5 males died on day 0, 3 females on day 0, 2 females on day 1) - Clinical signs:
- other: 500 mg/kg: Signs of hunched posture, pilo-erection and lethargy during day of dosing. All animals were normal on day 1. 1000 mg/kg: Hunched posture, pilo-erection, lethargy, decreased respiratory rate, occasional signs of increased salivation and ptosis
- Gross pathology:
- 500 mg/kg: one male showed a thickened area of the glandular region of the stomach
1000 mg/kg: one male showed an isolated finging of congested lungs.
2000 mg/kg: haemorrhage of the glandular and non-glandular regions of the stomach in animals that died during the study. Other occasional findings were congested lungs, dark livers and kindneys.
4000 mg/kg: Abnormal dark or congested appearances of the heart, lungs, liver, kidneys and spleen. The glandular and non-glandular regions of the stomach were severely haemorrhage with a sloughing of the inner lining. The large and small intestines were als haemorrhaged or congested.
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The LD50 determined in an acute oral study was 2000 mg/kg bw for males/females, 1625 mg/kg bw for males only and > 2000 mg/kg bw for females only.
- Executive summary:
The acute toxicity after oral application of the test substance was investigated in a GLP study according to OECD TG 401. Groups of 5 male and 5 female rats were dosed with 500, 1000, 2000 and 4000 mg/kg bw of the test substance by gavage. They were observed 1 and 4 hours after dosing and subsequently once daily for 14 days. All animals were subjected to gross necropsy examination.
No deaths occurred after application of 500 and 1000 mg/kg bw. The animals showed signs of hunched posture, pilo-erection and lethargy on day 0 but were all normal again on day 1. At necropsy, a thickened area of the glandular region of the stomach was observed in one male treated with 500 mg/kg bw. One male treated with 1000 mg/kg bw showed an isolated finging of congested lungs.
After application of 2000 mg/kg bw, 1 male was dead by day 0 and 3 males and 1 female were dead by day 1. The animals showed clinical signs such as hunched posture, pilo-erection, lethargy, ptosis, decreases resporatory rate and ataxia at the four hour observation. All surviving animlas gradually recovered and were normal 4 -5 days after treatment. In animals that died during the study, haemorrhage of the glandular and non-glandular regions of the stomach were noted at necropsy.
After application of 4000 mg/kg bw, all males and 3 females died on day 0. The remaining 2 females died on day 1. One hour after treatment, the animals showed signs of hunched posture, pilo-erection, leathargy, ptosis, increase salivation and decreased respiratory rate. The two females still alive at the 4 hour observation showed in addition occasional body tremors, ataxia, loss of righting reflex, pallor or the extremities and appeared thin and feeble. At necropsy, abnormal dark or congested appearances of the heart, lungs, liver, kidneys and spleen were observed. The stomach was severely haemorrhaged with a sloughing of the inner lining. The intestine was also haemorrhaged or congested.
In conclusion, the LD50 was determined to be 2000 mg/kg bw for males/females, 1625 mg/kg bw for males only and > 2000 mg/kg bw for females only.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.